Low Hemoglobin Tied to Increased Risks of Death, Hospitalization After TAVI

Other comorbidities may be contributing to anemia and cascading TAVI outcomes in aortic stenosis patients.

Low Hemoglobin Tied to Increased Risks of Death, Hospitalization After TAVI

Baseline anemia and declining periprocedural hemoglobin levels signal extra risk in patients with aortic stenosis (AS) undergoing TAVI, an analysis from the Cleveland Clinic shows.

Together and independently, the two factors associated with a higher risk for death at 3 years after TAVI, lead author Alexander Egoavil, BA (Cleveland Clinic, OH), and colleagues report in a manuscript published online last week in Structural Heart. Anemia also points to a significantly greater risk for heart failure (HF) hospitalization.

“The novel contribution of this study is the combined and additive impact of baseline anemia and periprocedural hemoglobin decline simultaneously,” the authors write.

“Both anemia and periprocedural blood loss are modifiable risk factors that extend beyond the procedural setting and have meaningful influence in midterm prognosis,” they note, adding that these risk factors “have the potential to support more tailored preprocedural optimization and postprocedural surveillance strategies, ultimately moving towards more personalized TAVR management.”

Modifiable Risk Factors

Egoavil and colleagues note that half of TAVI patients have anemia, in part because they tend to be older and frailer than those undergoing surgery; in surgical populations, only 16% to 36% have anemia. Hospitalization and mortality outcomes a few years after TAVI are underexplored in anemic patients.

This new study evaluated 1,666 patients treated with TAVI at the Cleveland Clinic between 2016 and 2020. Anemia was defined using World Health Organization criteria: hemoglobin < 13 g/dL in men and < 12 g/dL in women, with a periprocedural hemoglobin decline defined as ≥ 2 g/dL. Participants were excluded if they had prior cardiac implantable electronic devices, valve-in-valve TAVI, incomplete hemoglobin data, or major periprocedural bleeding.

The authors wrote that 38.1% of patients had no anemia with a small reduction in hemoglobin, 13.8% had no anemia with a large reduction, 41.7% had anemia but a small reduction, and 6.5% had anemia with a large hemoglobin reduction.

Across these four groups, death at 3 years post-TAVI increased stepwise: 13.9%, 23.4%, 31.4%, and 40.9%, respectively (P < 0.001). Compared with patients who had no anemia but had a small hemoglobin drop, those in the other three groups all had a significantly elevated mortality risk.

A similar stepwise increase in 3-year risk of HF hospitalization was observed across the four groups: 8.0%, 11.8%, 17.7%, 24.0% (P < 0.001). Compared with the no anemia/small drop group, only the two groups with baseline anemia had a significantly greater risk of HF hospitalization.

The patients with baseline anemia and a large periprocedural hemoglobin drop had the highest risks of mortality (HR 2.63; 95% CI 1.76-3.94) and HF hospitalization (HR 2.39; 95% CI 1.38-4.14) compared with the no anemia/small drop group.

Influence of Comorbidities

Dabit Arzamendi, MD, PhD (Hospital de la Santa Creu i Sant Pau, Barcelona, Spain), who was not involved in the study, said that “sometimes when patients come for TAVR, they are patients with several diseases that can explain this anemia.

“Probably the increase in mortality shown by this study is not just the hemoglobin,” he continued. “The hemoglobin is a sign of several comorbidities that the patients have.”

Those comorbidities vary, and it is important to “properly study” other conditions before patients undergo TAVI, said Arzamendi, pointing out that kidney disease, nutritional deficiencies, and gastrointestinal conditions are common in patients with AS. Egoavil et al note that 75% to 90% of anemia cases are related to iron deficiency in patients.

“If you have bleeding during a procedure, the mortality goes up to 40% . . . That’s why it’s important to try to get the hemoglobin levels lower before the procedure and [understand what] the mechanism [is],” said Arzamendi.

Arzamendi added that a CT scan covering the chest to the legs before TAVI can be beneficial in patients with AS who also have low hemoglobin levels because it allows radiologists to check for other diseases. If colon cancer is detected, for example, it might need to be treated before a patient undergoes TAVI.

“For patients that come into the consult with prior anemia, it’s a sign you need to check them, probably," said Arzamendi. “Before the [procedure], try to optimize everything so [patients] can get to the surgery with high hemoglobin levels.”

The authors note that, as TAVI has expanded from high-risk to low-risk patients, it’s become ever more important to understand the impact comorbidities have on postprocedural outcomes.

Bailey Salimes is a Medical Journalist at TCTMD. Prior to CRF, she was at MedStar Health Research Institute in Washington…

Read Full Bio
Sources
Disclosures
  • Egoavil reports no relevant conflicts of interest.

Comments